Close
A University of Missouri professor has identified new early-stage molecules to combat future coronaviruses. Dr. Dimitri Kireev ranked third in the CACHE Challenge, organized by the non-profit biotech company Conscience, which focused on using AI to predict drug development molecules. This challenge aimed to find molecules that could bind to coronaviruses, enhancing resistance to mutations.
The CACHE Challenge encourages collaboration in drug development, traditionally dominated by large pharmaceutical companies. Kireev's team utilized their AI model, FRASE-bot, to propose 100 potential molecules, with several confirmed as active. The results from this challenge are now publicly available, promoting wider participation in drug discovery.
• AI algorithms predicted new molecules for coronavirus drug development.
• Conscience facilitated experimental testing of AI-generated molecules at no cost.
These algorithms were employed in the CACHE Challenge to predict molecules that could effectively target coronaviruses.
Kireev's team used FRASE-bot to generate potential drug candidates for the CACHE Challenge.
Conscience organized the CACHE Challenge to promote collaboration and innovation in identifying new drug molecules.
Isomorphic Labs, the AI drug discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital for the first time. The $600
How to level up your teaching with AI. Discover how to use clones and GPTs in your classroom—personalized AI teaching is the future.
Trump's Third Term? AI already knows how this can be done. A study shows how OpenAI, Grok, DeepSeek & Google outline ways to dismantle U.S. democracy.
Sam Altman today revealed that OpenAI will release an open weight artificial intelligence model in the coming months. "We are excited to release a powerful new open-weight language model with reasoning in the coming months," Altman wrote on X.
Log in
Sign Up
AI Tools - Popular
AI Tools - Categories
GPTs - Categories
AI for Jobs
Key AI Highlights in this Article
Key AI Terms Mentioned in this Article
Companies Mentioned in this Article
